Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...
3D models provide a realistic environment for studying uveal melanoma They enable effective drug testing and personalized treatment approaches This research could lead to innovative therapies and ...
The leading Advanced Melanoma Companies such as OncoSec Medical, Immunocore, Sanofi, TILT Biotherapeutics, Novartis ...
We expect investors to focus on the sales performance of Immunocore Holdings plc’s IMCR sole marketed drug, Kimmtrak ...
Shares of Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) have been given a consensus rating of “Buy” by the seven ...
Background Increased pigmentation has been associated with cancer stem-cell-like behaviour and chemoresistance in uveal ...
Ideaya is financially strong, with $1.2 billion in cash reserves, sufficient to fund operations into at least 2028. Click ...
A benefit for South Lake Tahoe local Jennifer Milligin, who is recovering from Ocular Melanoma (eye cancer), will be held at ...
U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on ...
which is 49.0% of the diagnosed incident cases of ocular melanoma in 2023. In the US, out of all diagnosed incident cases of uveal melanoma, choroidal cases were highest, followed by ciliary body and ...